Maze Therapeutics, Inc. (MAZE) vs Rapport Therapeutics, Inc. Common Stock (RAPP)
A side-by-side comparison of Maze Therapeutics, Inc. and Rapport Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MAZE
Maze Therapeutics, Inc.
$26.16HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
RAPP
Rapport Therapeutics, Inc. Common Stock
$31.07HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — MAZE vs RAPP
growth of $100 · dividends reinvested · last 2yMAZE +65.7% (+28.7%/yr)RAPP +96.2% (+40.1%/yr)RAPP compounded faster over this window
MAZE RAPP
MAZE vs RAPP: by the numbers
- •RAPP is the larger company ($1.49B vs $1.45B market cap).
- •Both run net losses; MAZE's is the smaller (-667.95% vs -685.80% net margin).
Metrics side by side
Valuation
| Metric | MAZE | RAPP |
|---|---|---|
| P/S ratio | 72.39 | 74.29 |
| P/B ratio | 3.20 | 3.51 |
Profitability
| Metric | MAZE | RAPP |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | -667.95% | -685.80% |
| ROE | -29.48% | -32.43% |
| ROIC | -28.63% | -35.66% |
Go deeper
Dig into the metrics
Maze Therapeutics ROERapport Therapeutics, Inc. Common Stock ROEMaze Therapeutics operating marginRapport Therapeutics, Inc. Common Stock operating marginMaze Therapeutics revenue growthRapport Therapeutics, Inc. Common Stock revenue growthMaze Therapeutics free cash flowRapport Therapeutics, Inc. Common Stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.